Despite the emerging role of MDM4 (structural homologue of MDM2) in the pathogenesis, maintenance, and chemo-resistance of human cancer, there are currently no selective MDM4 antagonists undergoing clinical trial evaluation. The gene discussed is MDM2; the disease is cancer.